ClinicalTrials.gg
CompletedNCT00705783ASPIREUpdated Jul 19, 2013Results posted

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

A Phase 3 interventional study of Aripiprazole depot and Placebo depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 110 sites in 12 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-07-19.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
843
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
5th of 125
843 · median 130
Started
2008
with 7 others
Phase 3
34 of 126
1 open now
Registered
50th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 5th largest by enrollment of the 125 interventional ones that give a count, is one of 8 that started in 2008, is one of 34 in phase 3, and was the 50th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.

The trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient to be converted from their current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2, they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was stabilized, they were eligible to be randomized into the double-blind IM depot maintenance phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic symptoms and/or impending relapse for up to 52 weeks.

Read the detailed description

This was a randomized, double-blind, placebo-controlled study consisting of a screening phase and 4 treatment phases. Eligibility was determined during a screening phase of 2 to 42 days. Patients receiving oral treatment with an antipsychotic other than non-generic aripiprazole entered Phase 1. Patients with a lapse in aripiprazole or other antipsychotic treatment at the time of study entry ("lapse" defined as > 3 consecutive days without medication) entered directly into Phase 2. During Phase 1 (oral conversion), patients were cross-titrated during weekly visits from other antipsychotics to oral non-generic aripiprazole monotherapy over a minimum of 4 weeks and a maximum of 6 weeks. During Phase 2 (a minimum of 4 weeks and a maximum of 12 weeks in duration), patients were assessed bi-weekly and stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily. After stability criteria were met in Phase 2, patients entered the single-blind aripiprazole intramuscular (IM) depot stabilization phase, Phase 3. In Phase 3, patients were stabilized on aripiprazole IM depot for 12 consecutive weeks. Once the patient met the stability criteria, they were eligible to be randomized into the double-blind phase, Phase 4. Patients were randomized in a 2:1 ratio (aripiprazole IM depot vs placebo IM depot) stratified by region and last aripiprazole IM depot injection dose level in Phase 3. During Phase 4, patients were assessed for impending relapse/exacerbation of psychotic symptoms. If a patient was identified with impending relapse/exacerbation of psychotic symptoms, they were withdrawn from the trial and given the opportunity to enroll into an open-label aripiprazole IM depot trial, 31-08-248. Patients that completed Phase 4 (up to and including Week 52) had the option to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549).

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Aripiprazole
  • Intramuscular (IM) depot
  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are able to provide written and/or consent obtained from a legally acceptable representative (as required by the Institutional Review Board/Institutional Ethics Committee [IRB/IEC]), prior to the initiation of any protocol-required procedures.
  • Male and female subjects 18 to 60 years of age, inclusive, at time of informed consent.
  • Subjects with a current diagnosis of schizophrenia as defined by , 4th edition text revision (DSM-IV-TR) criteria and a history of the illness for at least 3 years prior to screening.
  • Subjects who, in the investigator's judgment, require chronic treatment with an antipsychotic medication.
  • Subjects able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, discontinuation of prohibited concomitant medications; who can read and understand the written word in order to complete patient-reported outcomes measures; and who can be reliably rated on assessment scales.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, or amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Subjects with schizophrenia that are considered resistant/ to antipsychotic treatment by history or response only to clozapine.
  • Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's judgment.
  • Subjects who currently meet DSM-IV-TR criteria for substance dependence, including alcohol and benzodiazepines, but excluding caffeine and nicotine; or 2 positive drug screens for cocaine.
  • Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones; or to antipsychotic agents.
  • Subjects with uncontrolled thyroid function abnormalities.
  • Subjects with a history of seizures, neuroleptic malignant syndrome, tardive dyskinesia, or other medical condition that would expose them to undue risk or interfere with study assessments.
  • Subjects who are involuntary incarcerated.
  • Subjects who have used an agent within 30 days of screening or prior participation in a clinical study with aripiprazole IM depot.
  • Subjects with clinically significant abnormalities in laboratory test results, vital signs, or results; and subjects hospitalized for more than 30 days in the 90 days prior to Phase 1.
  • Subjects who fail to wash-out from prohibited concomitant medications, including the use of CYP2D6 or inhibitors or CYP3A4 inducers, antipsychotics, antidepressants (including monoamine oxidase inhibitors [MAOI}), and mood stabilizers during screening and/or Phase 1.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
843 participants (actual)

Study arms

  • Experimental
    Aripiprazole depot

    Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.

    Drug: Aripiprazole depot

  • Placebo comparator
    Placebo depot

    Patients received placebo intramuscularly every 28 days for 52 weeks.

    Drug: Placebo depot

Interventions

  • DrugAripiprazoleStudies of AripiprazoleAripiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.

    Also known as: Abilify

  • DrugPlacebo depot

    Placebo depot was supplied in 400 mg lyophilized vials.

06

What researchers measure

Primary outcomes

  1. Time to Exacerbation of Psychotic Symptoms/Impending Relapse

    A patient experienced an exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score \> 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score \> 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

Secondary outcomes

  1. Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria

    This is the key secondary Outcome Measure.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

  2. Percentage of Responders

    A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

  3. Percentage of Patients Achieving Remission

    A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

  4. Mean Change From Baseline in the PANSS Total Score

    The PANSS consists of 3 subscales (Positive Subscale, 7 constructs, scores ranged from 7-49, Negative Subscale, 7 constructs, scores ranged from 7-49, General Psychopathology Subscale, 16 constructs, scores ranged from 16-112) containing a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30-210 with a higher score indicating more severe symptoms. A negative change score indicates improvement.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

  5. Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score

    The severity of illness for each patient was rated using the CGI-S. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The CGI-S score ranged from 0-7 with a higher score indicating greater illness. A negative change score indicates improvement.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

  6. Mean Change From Baseline in the PANSS Positive Subscale Score

    The PANSS Positive Subscale consists of 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

  7. Mean Change From Baseline in the PANSS Negative Subscale Score

    The PANSS Negative Subscale consists of 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

  8. Mean Clinical Global Impression-Improvement (CGI-I) Score

    The efficacy of the study medication was rated for each patient using the CGI-I scale. The rater or investigator rated the patient's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the patient's condition at Baseline. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I score ranged from 0-7 with a higher score indicating less improvement/worsening.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

  9. Time to Discontinuation

    Time to discontinuation was defined as the date of randomization to the date of study discontinuation.

    Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)

07

Results

Posted Jul 19, 2013

Participant flow

Conversion Phase
Participant flow — Conversion Phase
MilestoneAll PatientsAripiprazole DepotPlacebo Depot
Started63300
Received study medication63200
Completed50000
Not completed13300
Withdrew: Sponsor discontinued study5400
Withdrew: Lost to follow-up1300
Withdrew: Met withdrawal criteria400
Withdrew: Withdrawn by investigator400
Withdrew: Withdrew consent2400
Withdrew: Protocol deviation200
Withdrew: Adverse event1100
Withdrew: Lack of efficacy with adverse event1300
Withdrew: Lack of efficacy without adverse event800
Oral Stabilization Phase
Participant flow — Oral Stabilization Phase
MilestoneAll PatientsAripiprazole DepotPlacebo Depot
Started71000
Received study medication70900
Completed57600
Not completed13400
Withdrew: Sponsor discontinue study4200
Withdrew: Lost to follow-up700
Withdrew: Met withdrawal criteria1900
Withdrew: Withdrawn by investigator1200
Withdrew: Withdrew consent2900
Withdrew: Adverse event1400
Withdrew: Lack of efficacy with adverse event700
Withdrew: Lack of efficacy without adverse event400
Depot Stabilization Phase
Participant flow — Depot Stabilization Phase
MilestoneAll PatientsAripiprazole DepotPlacebo Depot
Started57600
Completed40300
Not completed17300
Withdrew: Sponsor discontinued study8600
Withdrew: Lost to follow-up1100
Withdrew: Met withdrawal criteria800
Withdrew: Withdrawn by investigator900
Withdrew: Withdrew consent2900
Withdrew: Adverse event1700
Withdrew: Lack of efficacy with adverse event1200
Withdrew: Lack of efficacy without adverse event100
Depot Maintenance Phase
Participant flow — Depot Maintenance Phase
MilestoneAll PatientsAripiprazole DepotPlacebo Depot
Started0269134
Completed0233
Not completed0246131
Withdrew: Sponsor discontinued study017958
Withdrew: Lost to follow-up053
Withdrew: Met withdrawal criteria022
Withdrew: Withdrawn by investigator086
Withdrew: Withdrew consent0144
Withdrew: Protocol deviation020
Withdrew: Adverse event without impending relapse095
Withdrew: Impending relapse with adverse event01113
Withdrew: Impending relapse without adverse event01640

Outcome measures

PrimaryTime to Exacerbation of Psychotic Symptoms/Impending Relapse

A patient experienced an exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score \> 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score \> 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Median · Days
Time to Exacerbation of Psychotic Symptoms/Impending Relapse
DaysAripiprazole DepotPlacebo Depot
Time to Exacerbation of Psychotic Symptoms/Impending RelapseNA (NA to NA)209 (161 to 254)
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.199 · 95% CI 0.125 to 0.317Aripiprazole depot/placebo depot
SecondaryPercentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria

This is the key secondary Outcome Measure.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Number · Percentage of patients
Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria
Percentage of patientsAripiprazole DepotPlacebo Depot
Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria10.039.6
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · Chi-squared · p = <0.0001 (The alpha levels for this key secondary Outcome Measure were the same as used for the primary Outcome Measure.)
SecondaryPercentage of Responders

A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Number · Percentage of patients
Percentage of Responders
Percentage of patientsAripiprazole DepotPlacebo Depot
Percentage of Responders87.656.0
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · Chi-squared · p = <0.0001
SecondaryPercentage of Patients Achieving Remission

A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Remission
Percentage of patientsAripiprazole DepotPlacebo Depot
Percentage of Patients Achieving Remission52.938.7
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · Chi-squared · p = 0.1756
SecondaryMean Change From Baseline in the PANSS Total Score

The PANSS consists of 3 subscales (Positive Subscale, 7 constructs, scores ranged from 7-49, Negative Subscale, 7 constructs, scores ranged from 7-49, General Psychopathology Subscale, 16 constructs, scores ranged from 16-112) containing a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30-210 with a higher score indicating more severe symptoms. A negative change score indicates improvement.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the PANSS Total Score
Units on a scaleAripiprazole DepotPlacebo Depot
Mean Change From Baseline in the PANSS Total Score1.43 ± 0.75611.55 ± 1.066
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · ANCOVA · p = <0.0001 · Mean difference (final values): -10.11 · 95% CI -12.68 to -7.54The ANCOVA included treatment as a term and baseline as a covariate.
SecondaryMean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score

The severity of illness for each patient was rated using the CGI-S. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The CGI-S score ranged from 0-7 with a higher score indicating greater illness. A negative change score indicates improvement.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Mean · Units on a scale
Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score
Units on a scaleAripiprazole DepotPlacebo Depot
Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score0.14 ± 0.0510.66 ± 0.073
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · ANCOVA · p = <0.0001 · Mean difference (final values): -0.52 · 95% CI -0.70 to -0.35The ANCOVA included treatment as a term and baseline as a covariate.
SecondaryMean Change From Baseline in the PANSS Positive Subscale Score

The PANSS Positive Subscale consists of 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the PANSS Positive Subscale Score
Units on a scaleAripiprazole DepotPlacebo Depot
Mean Change From Baseline in the PANSS Positive Subscale Score0.44 ± 0.2654.25 ± 0.374
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · ANCOVA · p = <0.0001 · Mean difference (final values): -3.82 · 95% CI -4.72 to -2.91The ANCOVA included treatment as a term and baseline as a covariate.
SecondaryMean Change From Baseline in the PANSS Negative Subscale Score

The PANSS Negative Subscale consists of 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the PANSS Negative Subscale Score
Units on a scaleAripiprazole DepotPlacebo Depot
Mean Change From Baseline in the PANSS Negative Subscale Score0.19 ± 0.2011.55 ± 0.284
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · ANCOVA · p = 0.0001 · Mean difference (final values): -1.36 · 95% CI -2.04 to -0.67The ANCOVA included treatment as a term and baseline as a covariate.
SecondaryMean Clinical Global Impression-Improvement (CGI-I) Score

The efficacy of the study medication was rated for each patient using the CGI-I scale. The rater or investigator rated the patient's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the patient's condition at Baseline. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I score ranged from 0-7 with a higher score indicating less improvement/worsening.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression-Improvement (CGI-I) Score
Units on a scaleAripiprazole DepotPlacebo Depot
Mean Clinical Global Impression-Improvement (CGI-I) Score3.70 ± 1.054.53 ± 1.23
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryTime to Discontinuation

Time to discontinuation was defined as the date of randomization to the date of study discontinuation.

Time frame:
Baseline of the depot maintenance phase to the end of the study (Week 52)
Reported as:
Median · Days
Time to Discontinuation
DaysAripiprazole DepotPlacebo Depot
Time to DiscontinuationNA (364 to NA)162 (98 to 211)
Statistical analysis
  • Aripiprazole Depot vs Placebo Depot · Log Rank · p = <0.0001

Adverse events

Collected over Adverse events were reported from the time of the signing of informed consent until the end of the study (up to 106 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Conversion Phase—13/632 (2.1%)113/632 (17.9%)
Oral Stabilization Phase—10/709 (1.4%)50/709 (7.1%)
Depot Stabilization Phase—25/576 (4.3%)184/576 (31.9%)
Aripiprazole Depot - Depot Maintenance Phase—11/269 (4.1%)103/269 (38.3%)
Placebo Depot - Depot Maintenance Phase—9/134 (6.7%)43/134 (32.1%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventConversion PhaseOral Stabilization PhaseDepot Stabilization PhaseAripiprazole Depot - Depot Maintenance PhasePlacebo Depot - Depot Maintenance Phase
Psychotic disorderPsychiatric disorders2/6321/7092/5764/2694/134
SchizophreniaPsychiatric disorders6/6326/7099/5762/2692/134
Sinus bradycardiaCardiac disorders0/6320/7090/5760/2691/134
DiarrhoeaGastrointestinal disorders0/6320/7090/5760/2691/134
Biliary colicHepatobiliary disorders0/6320/7090/5760/2691/134
Grand mal convulsionNervous system disorders0/6320/7090/5760/2691/134
Suicidal ideationPsychiatric disorders2/6320/7090/5762/2690/134
Gun shot woundInjury, poisoning and procedural complications0/6320/7090/5761/2690/134
InjuryInjury, poisoning and procedural complications0/6320/7090/5761/2690/134
Multiple injuriesInjury, poisoning and procedural complications0/6320/7090/5761/2690/134
Most frequent other events
Most frequent other events
EventConversion PhaseOral Stabilization PhaseDepot Stabilization PhaseAripiprazole Depot - Depot Maintenance PhasePlacebo Depot - Depot Maintenance Phase
InsomniaPsychiatric disorders76/63250/70946/57627/26912/134
Weight increasedInvestigations8/63216/70940/57626/26913/134
AnxietyPsychiatric disorders27/63229/70938/57616/26910/134
HeadacheNervous system disorders45/63223/70934/57616/2697/134
AkathisiaNervous system disorders30/63233/70936/57615/2698/134
TremorNervous system disorders16/63214/70921/57616/2692/134
Injection site painGeneral disorders0/6322/70934/5768/2695/134
NasopharyngitisInfections and infestations14/6326/70911/57610/2697/134

Baseline characteristics

Baseline measures are based on the participants from the Depot Maintenance Phase.

Age Continuous
Age Continuous(years)Aripiprazole DepotPlacebo DepotTotal
Mean40.1 ± 11.041.7 ± 10.540.6 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole DepotPlacebo DepotTotal
Female10755162
Male16279241
08

Study locations

110 sites
  • Otsuka Investigational Site
    Chandler, Arizona 85226, United States
  • Otsuka Investigational Site
    Anaheim, California 92805, United States
  • Otsuka Investigational Site
    National City, California 91950, United States
  • Otsuka Investigational Site
    Oceanside, California 92056, United States
  • Otsuka Investigational Site
    San Diego, California 92123, United States
  • Otsuka Investigational Site
    Santa Ana, California 92701, United States
  • Otsuka Investigational Site
    Highlands Ranch, Colorado 80130, United States
  • Otsuka Investigational Site
    Norwalk, Connecticut 06851, United States
  • Otsuka Investigational Site
    Altamonte Springs, Florida 32701, United States
  • Otsuka Investigational Site
    Bradenton, Florida 34208, United States
  • Otsuka Investigational Site
    Hollywood, Florida 33021, United States
  • Otsuka Investigational Site
    Maitland, Florida 32751, United States
  • Otsuka Investigational Site
    Miami, Florida 33135, United States
  • Otsuka Investigational Site
    North Miami, Florida 33161, United States
  • Otsuka Investigational Site
    Orange City, Florida 32763, United States
  • Otsuka Investigational Site
    Tampa, Florida 33613, United States
  • Otsuka Investigational Site
    Atlanta, Georgia 30328, United States
  • Otsuka Investigational Site
    Hoffman Estates, Illinois 60169, United States
  • Otsuka Investigational Site
    Munster, Indiana 46321, United States
  • Otsuka Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Otsuka Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • Otsuka Investigational Site
    Lake Charles, Louisiana 70601, United States
  • Otsuka Investigational Site
    New Orleans, Louisiana 70115, United States
  • Otsuka Investigational Site
    Columbia, Maryland 21045, United States
  • Otsuka Investigational Site
    Flowood, Mississippi 39232, United States
  • Otsuka Investigational Site
    St. Louis, Missouri 63118, United States
  • Otsuka Investigational Site
    North Platte, Nebraska 69101, United States
  • Otsuka Investigational Site
    Albuquerque, New Mexico 87131, United States
  • Otsuka Investigational Site
    Buffalo, New York 14215, United States
  • Otsuka Investigational Site
    Cedarhurst, New York 11516, United States
  • Otsuka Investigational Site
    Elmsford, New York 10523, United States
  • Otsuka Investigational Site
    Holliswood, New York 11423, United States
  • Otsuka Investigational Site
    Jamaica, New York 11418, United States
  • Otsuka Investigational Site
    Staten Island, New York 10305, United States
  • Otsuka Investigational Site
    Cleveland, Ohio 44109, United States
  • Otsuka Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Otsuka Investigational Site
    Philadelphia, Pennsylvania 19131, United States
  • Otsuka Investigational Site
    Memphis, Tennessee 38119, United States
  • Otsuka Investigational Site
    Austin, Texas 78754, United States
  • Otsuka Investigational Site
    DeSoto, Texas 75115, United States
  • Otsuka Investigational Site
    Bellevue, Washington 98007, United States
  • Otsuka Investigational Site
    Bothell, Washington 98011, United States
  • Otsuka Investigational Site
    Richland, Washington 99354, United States
  • Otsuka Investigational Site
    Ciudad Autónoma de Bs. As., Buenos Aires C1058AAJ, Argentina
  • Otsuka Investigational Site
    La Plata, Buenos Aires 1900, Argentina
  • Otsuka Investigational Site
    Lanús Este, Buenos Aires B1834IBR, Argentina
  • Otsuka Investigational Site
    Pueyrredón, Cordoba X5004ALB, Argentina
  • Otsuka Investigational Site
    Rosario, Santa Fe 2000, Argentina
  • Otsuka Investigational Site
    Buenos Aires, C1405BOA, Argentina
  • Otsuka Investigational Site
    Buenos Aires, C1425AHQ, Argentina
  • Otsuka Investigational Site
    Cordoba, X5009BIN, Argentina
  • Otsuka Investigational Site
    Mendoza, 5500HYF, Argentina
  • Otsuka Investigational Site
    Mendoza, 5500, Argentina
  • Otsuka Investigational Site
    Lovech, 5500, Bulgaria
  • Otsuka Investigational Site
    Pleven, 5800, Bulgaria
  • Otsuka Investigational Site
    Plovdiv, 4002, Bulgaria
  • Otsuka Investigational Site
    Radnevo, 6260, Bulgaria
  • Otsuka Investigational Site
    Region of Veliko Tarnovo, 5047, Bulgaria
  • Otsuka Investigational Site
    Rousse, 7000, Bulgaria
  • Otsuka Investigational Site
    Sofia, 1113, Bulgaria
  • Otsuka Investigational Site
    Varna, 9010, Bulgaria
  • Otsuka Investigational Site
    Ahmedabad, Gujarat 380006, India
  • Otsuka Investigational Site
    Bangalore, Karnataka 560010, India
  • Otsuka Investigational Site
    Chennai, Tamil Nadu 600003, India
  • Otsuka Investigational Site
    Kanpur, 208005, India
  • Otsuka Investigational Site
    Mangalore, 575018, India
  • Otsuka Investigational Site
    Pune, 411004, India
  • Otsuka Investigational Site
    Tirupati, 517507, India
  • Otsuka Investigational Site
    Cheras, Kuala Lumpur 56000, Malaysia
  • Otsuka Investigational Site
    Tanjong Rambutan, Perak 31250, Malaysia
  • Otsuka Investigational Site
    Kuala Lumpur, Wilayah Persekutuan 50603, Malaysia
  • Otsuka Investigational Site
    Selangor, 43000, Malaysia
  • Otsuka Investigational Site
    Mexico, DF 6700, Mexico
  • Otsuka Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • Otsuka Investigational Site
    Monterrey, Nuevo León 64040, Mexico
  • Otsuka Investigational Site
    Culiacan, Sinaloa 80020, Mexico
  • Otsuka Investigational Site
    San Luis Potosí, 78218, Mexico
  • Otsuka Investigational Site
    Bataan, Central Luzon 2105, Philippines
  • Otsuka Investigational Site
    Mandaluyong, NCR 1553, Philippines
  • Otsuka Investigational Site
    Quezon City, NCR 1104, Philippines
  • Otsuka Investigational Site
    Iloilo, Western Visayas 5000, Philippines
  • Otsuka Investigational Site
    Cebu City, 6000, Philippines
  • Otsuka Investigational Site
    Arad, 310022, Romania
  • Otsuka Investigational Site
    Bucuresti, 041914, Romania
  • Otsuka Investigational Site
    Cluj-Napoca, 400012, Romania
  • Otsuka Investigational Site
    Craiova, 200620, Romania
  • Otsuka Investigational Site
    Oradea, 410154, Romania
  • Otsuka Investigational Site
    Pitesti, 110069, Romania
  • Otsuka Investigational Site
    Lipetsk, 399083, Russian Federation
  • Otsuka Investigational Site
    Moscow, 115409, Russian Federation
  • Otsuka Investigational Site
    Moscow, 115522, Russian Federation
  • Otsuka Investigational Site
    Moscow, 127473, Russian Federation
  • Otsuka Investigational Site
    Nizhny Novgorod, 603107, Russian Federation
  • Otsuka Investigational Site
    Nizhny Novgorod, 603155, Russian Federation
  • Otsuka Investigational Site
    Smolensk, 214019, Russian Federation
  • Otsuka Investigational Site
    St. Petersburg, 188357, Russian Federation
  • Otsuka Investigational Site
    St. Petersburg, 190121, Russian Federation
  • Otsuka Investigational Site
    St. Petersburg, 192019, Russian Federation
  • Otsuka Investigational Site
    Belgrade, 11000, Serbia
  • Otsuka Investigational Site
    Kragujevac, 34000, Serbia

Showing the first 100 of 110 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012 May;73(5):617-24. doi: 10.4088/JCP.11m07530. PubMed 22697189 ↗
  • Kane JM, Sanchez R, Baker RA, Eramo A, Peters-Strickland T, Perry PP, Johnson BR, Tsai LF, Carson WH, McQuade RD, Fleischhacker WW. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clin Schizophr Relat Psychoses. 2015 Summer;9(2):79-87. doi: 10.3371/CSRP.KASA.022015. Epub 2015 Feb 24. PubMed 25711509 ↗
  • Fleischhacker WW, Sanchez R, Johnson B, Jin N, Forbes RA, McQuade R, Baker RA, Carson W, Kane JM. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 2013 Jul;28(4):171-6. doi: 10.1097/YIC.0b013e3283615dba. PubMed 23615694 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Aug 2010 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 2 years 11 months after primary completion. A results delay was requested in Sep 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2008
First posted
Jun 26, 2008
Start
Jul 2008
Primary completionActual
Aug 2010
CompletionActual
Feb 2011
Results delay requested
Sep 2, 2011
Results first posted
Jul 19, 2013
Last update
Jul 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00705783
Responsible party
Sponsor
First posted
Jun 26, 2008
Start date
Jul 2008
Primary completion
Aug 2010
Completion
Feb 2011
Results posted
Jul 19, 2013
Last update
Jul 19, 2013

Study contacts

Raymond Sanchez, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion